JP2013520174A5 - - Google Patents

Info

Publication number

JP2013520174A5

JP2013520174A5 JP2012554083A JP2012554083A JP2013520174A5 JP 2013520174 A5 JP2013520174 A5 JP 2013520174A5 JP 2012554083 A JP2012554083 A JP 2012554083A JP 2012554083 A JP2012554083 A JP 2012554083A JP 2013520174 A5 JP2013520174 A5 JP 2013520174A5

Authority

JP

Japan

Prior art keywords

antibody

seq

cancer

mammal

sequence

Prior art date

2011-02-22

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 206010028980 Neoplasm Diseases 0.000 claims 17
• 210000004027 cell Anatomy 0.000 claims 17
• 201000011510 cancer Diseases 0.000 claims 16
• 241000124008 Mammalia Species 0.000 claims 13
• 108090000623 proteins and genes Proteins 0.000 claims 13
• 229920001184 polypeptide Polymers 0.000 claims 11
• 108090000765 processed proteins & peptides Proteins 0.000 claims 11
• 102000004196 processed proteins & peptides Human genes 0.000 claims 11
• 239000000523 sample Substances 0.000 claims 11
• 238000000034 method Methods 0.000 claims 8
• 102000004169 proteins and genes Human genes 0.000 claims 7
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 6
• 208000034578 Multiple myelomas Diseases 0.000 claims 4
• 206010035226 Plasma cell myeloma Diseases 0.000 claims 4
• 239000013068 control sample Substances 0.000 claims 4
• 201000001441 melanoma Diseases 0.000 claims 4
• 230000015572 biosynthetic process Effects 0.000 claims 3
• 108091034117 Oligonucleotide Proteins 0.000 claims 2
• 238000010240 RT-PCR analysis Methods 0.000 claims 2
• IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 claims 2
• NLMBVBUNULOTNS-HOKPPMCLSA-N [4-[[(2s)-5-(carbamoylamino)-2-[[(2s)-2-[6-(2,5-dioxopyrrol-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl n-[(2s)-1-[[(2s)-1-[[(3r,4s,5s)-1-[(2s)-2-[(1r,2r)-3-[[(1s,2r)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-o Chemical group C1([C@H](O)[C@@H](C)NC(=O)[C@H](C)[C@@H](OC)[C@@H]2CCCN2C(=O)C[C@H]([C@H]([C@@H](C)CC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCC=2C=CC(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN3C(C=CC3=O)=O)C(C)C)=CC=2)C(C)C)OC)=CC=CC=C1 NLMBVBUNULOTNS-HOKPPMCLSA-N 0.000 claims 2
• 125000003275 alpha amino acid group Chemical group 0.000 claims 2
• 108010044540 auristatin Proteins 0.000 claims 2
• 229940127089 cytotoxic agent Drugs 0.000 claims 2
• 239000002254 cytotoxic agent Substances 0.000 claims 2
• 231100000599 cytotoxic agent Toxicity 0.000 claims 2
• 238000013388 immunohistochemistry analysis Methods 0.000 claims 2
• 238000007901 in situ hybridization Methods 0.000 claims 2
• 239000000203 mixture Substances 0.000 claims 2
• 108010093470 monomethyl auristatin E Proteins 0.000 claims 2
• 239000003053 toxin Substances 0.000 claims 2
• 231100000765 toxin Toxicity 0.000 claims 2
• 108700012359 toxins Proteins 0.000 claims 2
• 238000001262 western blot Methods 0.000 claims 2
• 241000894006 Bacteria Species 0.000 claims 1
• 108090000790 Enzymes Proteins 0.000 claims 1
• 102000004190 Enzymes Human genes 0.000 claims 1
• 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
• 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
• 241001465754 Metazoa Species 0.000 claims 1
• 150000001413 amino acids Chemical class 0.000 claims 1
• 239000003242 anti bacterial agent Substances 0.000 claims 1
• 229940088710 antibiotic agent Drugs 0.000 claims 1
• HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 claims 1
• 229930195731 calicheamicin Natural products 0.000 claims 1
• 239000003795 chemical substances by application Substances 0.000 claims 1
• 210000004978 chinese hamster ovary cell Anatomy 0.000 claims 1
• 108020004707 nucleic acids Proteins 0.000 claims 1
• 102000039446 nucleic acids Human genes 0.000 claims 1
• 150000007523 nucleic acids Chemical class 0.000 claims 1
• 230000001293 nucleolytic effect Effects 0.000 claims 1
• 239000008194 pharmaceutical composition Substances 0.000 claims 1
• 230000035755 proliferation Effects 0.000 claims 1